시장보고서
상품코드
1170875

두경부암 치료제 시장 규모, 점유율, 동향 분석 리포트 : 치료 유형별(화학요법, 면역치료, 표적치료), 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2022-2030년)

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

두경부암 치료제 시장의 성장과 동향

Grand View Research, Inc.의 새로운 리포트에 따르면 세계의 두경부암 치료제 시장 규모는 2030년까지 35억 달러에 달할 것으로 예측되고 있습니다. 이 시장은 2022-2030년 CAGR 12.5%로 확대할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

  • 시장 세분화
    • 부문의 범위
    • 지역 범위
  • 조사 방법
  • 정보 조달
    • 구입한 데이터베이스
    • GVR의 내부 데이터베이스
    • 2차 정보
    • 1차 조사
    • 1차 조사 내용
  • 정보 또는 데이터 분석
    • 데이터 분석 모델
  • 시장 책정과 검증
  • 모델 상세
    • 상품 플로우 분석
      • 어프로치 1 : 상품 플로우 어프로치
      • 어프로치 2 : 보텀업 어프로치를 사용한 국가별 시장 추정
      • 어프로치 3 : 톱다운 어프로치를 사용한 국가별 시장 추정
  • 세계 시장 : CAGR 계산
  • 조사의 가정
  • 주요 KoL 응답
  • 시장 점유율 계산
  • 2차 정보 리스트
  • 목적
  • 약어 리스트

제2장 주요 요약

  • 시장 개요

제3장 두경부암 치료제 시장 - 업계 전망

  • 시장 계열 전망
    • 모시장 계통 전망
    • 관련/보조적인 시장 전망
  • 침투와 성장 전망 매핑
  • 시장 역학
    • 시장 촉진요인 분석
      • 두경부암의 유병률 증가
      • 고령자 인구의 증가
      • 연구개발의 증가와 파이프라인 제품의 강력한 존재감
      • 지원적 상환 정책과 질병에 대한 의식의 향상
    • 시장 억제요인 분석
      • 안전성과 유효성에 관한 데이터의 부족
      • 고액의 치료비
  • 두경부암 치료 시장 분석 툴
    • 업계 분석 - Porter's
    • SWOT 분석, 요인별(정치와 법률, 경제와 기술)
      • 정치와 법률
      • 경제와 사회
      • 기술
  • 상환과 규제 시나리오
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • MEA
  • 주요 거래와 전략적 제휴
    • 신제품 발매
    • 취득
    • 확장
    • 파트너십
  • 파이프라인 분석

제4장 두경부암 치료제 시장 분석 : 치료 유형의 범위, 2018-2030년(매출, 100만 달러)

  • 두경부암 치료제 시장 : 치료 유형 변동 분석
  • 화학요법
  • 면역치료
  • 표적치료

제5장 두경부암 치료제 시장 분석 : 투여 범위 경로, 2018-2030년(매출, 100만 달러)

  • 두경부암 치료제 시장 : 투여 경로 변동 분석
  • 주사제
  • 경구

제6장 두경부암 치료제 시장 분석 : 유통 채널의 범위, 2018-2030년(매출, 100만 달러)

  • 두경부암 치료제 시장 : 유통 채널 변동 분석
  • 소매 및 전문 약국
  • 병원 약국
  • 온라인 약국

제7장 두경부암 치료제 시장 분석, 지역 범위, 2017-2030년,(매출, 100만 달러)

  • 2021년과 2030년 지역별 시장 점유율 분석
    • 북미
      • 미국
      • 캐나다
    • 유럽
      • 영국
      • 독일
      • 프랑스
      • 이탈리아
      • 스페인
    • 아시아태평양
      • 일본
      • 중국
      • 인도
      • 호주
      • 한국
    • 라틴아메리카
      • 브라질
      • 멕시코
      • 아르헨티나
    • 중동 및 아프리카(MEA)
      • 남아프리카공화국
      • 사우디아라비아
      • 남아프리카공화국

제8장 두경부암 치료제 시장 : 경쟁 분석

  • 주요 시장 참여 기업별 최근 동향과 영향 분석
    • Ansoff matrix
  • 회사 분류
    • 이노베이터
      • 시장 차별화 요인
  • 벤더 구도
    • 주요 유통업체와 채널 파트너 리스트
    • 주요 고객
    • 주요 기업의 시장 점유율 분석, 2020년
  • 공개 회사
    • 회사 시장 현황 분석
    • 경쟁 대시보드 분석
  • 비공개 회사
    • 주요 신규 기업 리스트
  • Regional Network Map
  • 기업 개요
    • Eli Lilly and Company
      • 회사 개요
      • 재무 실적
      • 제품 벤치마킹
      • 전략적 구상
    • Sanofi
      • 회사 개요
      • 재무 실적
      • 제품 벤치마킹
      • 전략적 구상
    • Merck &Co., Inc.
      • 회사 개요
      • 재무 실적
      • 제품 벤치마킹
      • 전략적 구상
    • Clingen Group plc.
      • 회사 개요
      • 재무 실적
      • 제품 벤치마킹
      • 전략적 구상
    • Bristol-Mayers Squibb Company
      • 회사 개요
      • 아피메트릭스
      • 회사 개요
      • 재무 실적
      • 제품 벤치마킹
      • 전략적 구상
    • Takeda Pharmaceutical Company Limited
      • 회사 개요
      • 재무 실적
      • 제품 벤치마킹
      • 전략적 구상
    • Teva Pharmaceutical Industries Ltd
      • 회사 개요
      • 재무 실적
      • 제품 벤치마킹
      • 전략적 구상
    • F. Hoffmann-La Roche Ltd.
      • 회사 개요
      • 재무 실적
      • 제품 벤치마킹
      • 전략적 구상
KSA 22.12.22

Head And Neck Cancer Therapeutics Market Growth & Trends:

The global head and neck cancer therapeutics market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.5% from 2022 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Head And Neck Cancer Therapeutics Market Report Highlights:

  • By therapy type, the immunotherapy segment held the largest market share in 2021 due to the presence of supportive reimbursement policies and the higher efficacy of immunotherapy drugs as an effective treatment for head and neck cancer diseases
  • By route of administration, the oral segment is expected to be the fastest-growing segment during the forecast period. This can be attributed to the high safety, efficacy, and tolerability associated with this route of administration among rare disease patients
  • By distribution channel, the retail and specialty pharmacy segment dominated the market in 2021. This dominance can be attributed to the preference of oncologists for specialty pharmacies. Oncologists often need specialty pharmacies so that with extensive therapeutic knowledge, they can support treatment plans and relieve them from the administrative burden
  • Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the entry of new products into the region. For instance, in 2020, NMPA approved ERBITUX (Cetuximab) developed by Merck and Co., Inc., to treat patients with head and neck cancer in China

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity flow approach
      • 1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
      • 1.6.1.3 Approach 3: Country wise market estimation using top down approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 Key KoL Responses
  • 1.10 Market Share Calculations
  • 1.11 List of Secondary Sources
  • 1.12 Objectives
    • 1.12.1 Objective 1:
    • 1.12.2 Objective 2:
  • 1.13 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Head and Neck Cancer Therapeutics Market - Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Lineage Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers Analysis
      • 3.3.1.1 Increasing prevalence of head and neck cancers
      • 3.3.1.2 Rising geriatric population
      • 3.3.1.3 Increasing R&D and strong presence of pipeline product
      • 3.3.1.4 Supportive reimbursment policies and rising awareness about disease
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Paucity of data related to safety and efficacy
      • 3.3.2.2 High cost of treatments
  • 3.4 Head and Neck Cancer Therapeutics Market Analysis Tools
    • 3.4.2 Industry Analysis - Porter's
    • 3.4.3 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
      • 3.4.3.1 Political and Legal
      • 3.4.3.2 Economic & Social
      • 3.4.3.3 Technological
  • 3.5 Reimbursement & Regulatory Scenario
    • 3.5.1 North America
    • 3.5.1 Europe
    • 3.5.2 Asia Pacific
    • 3.5.3 Latin America
    • 3.5.4 MEA
  • 3.6 Major Deals & Strategic Alliances
    • 3.6.1 New Product Launch
    • 3.6.2 Acquisition
    • 3.6.3 Expansion
    • 3.6.4 Partnerships
  • 3.7 Pipeline analysis

Chapter 4 Head and Neck Cancer Therapeutics Market Analysis: Therapy Type Scope, 2018 - 2030 (Revenue, USD Million)

  • 4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
  • 4.2 Chemotherapy
    • 4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.3 Immunotherapy
    • 4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.4 Targeted Therapy
    • 4.4.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)

Chapter 5 Head and Neck Cancer Therapeutics Market Analysis: Route of Administration Scope, 2018 - 2030 (Revenue, USD Million)

  • 5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
  • 5.2 Injectables
    • 5.2.1 Injectables market estimates and forecast, 2018 - 2030 (USD million)
  • 5.3 Oral
    • 5.3.1 Oral market estimates and forecast, 2018 - 2030 (USD million)

Chapter 6 Head and Neck Cancer Therapeutics Market Analysis: Distribution Channel Scope, 2018 - 2030 (Revenue, USD Million)

  • 6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
  • 6.2 Retail & Specialty Pharmacies
    • 6.2.1 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)
  • 6.3 Hospital Pharmacies
    • 6.3.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
  • 6.4 Online Pharmacies
    • 6.4.1 Online pharmacies market estimates and forecast, 2018 - 2030 (USD million)

Chapter 7 Head and Neck Cancer Therapeutics Market Analysis, Regional Scope, 2017-2030, (Revenue, USD Million)

  • 7.1 Market Share Analysis by Regional, 2021 & 2030
    • 7.1.1 North America
      • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.2 U.S.
      • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.3 Canada
      • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2 Europe
      • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.2 U.K.
      • 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.3 Germany
      • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.4 France
      • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.5 Italy
      • 7.1.2.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.6 Spain
      • 7.1.2.6.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3 Asia Pacific
      • 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.2 Japan
      • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 China
      • 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 India
      • 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.5 Australia
      • 7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.6 South Korea
      • 7.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4 Latin America
      • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.2 Brazil
      • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 Mexico
      • 7.1.3.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 Argentina
      • 7.1.3.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5 Middle East and Africa (MEA)
      • 7.1.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.8.2 South Africa
      • 7.1.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 Saudi Arabia
      • 7.1.3.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 South Africa
      • 7.1.3.4.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Head and Neck Cancer Therapeutics Market: Competitive Analysis

  • 8.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 8.1.1 Ansoff matrix`
  • 8.2 Company Categorization
    • 8.2.1 Innovators
      • 8.2.2.1 Market Differentiators
  • 8.3 Vendor Landscape
    • 8.3.1 List of Key Distributors And Channel Partners
    • 8.3.2 Key Customers
    • 8.3.3 Key Company Market Share Analysis, 2020
  • 8.4 Public Companies
    • 8.4.1 Comapany Market Position analysis
    • 8.4.2 Competitive dashboard analysis
  • 8.5 Private Companies
    • 8.5.1 List of Key Emerging Companies
  • 8.6 Regional Network Map
  • 8.8 Company Profiles
    • 8.8.1 Eli Lilly and Company
      • 8.8.1.1 Company overview
      • 8.8.1.2 Financial performance
      • 8.8.1.3 Product benchmarking
      • 8.8.1.4 Strategic initiatives
    • 8.8.2 Sanofi
      • 8.8.2.1 Company overview
      • 8.8.2.2 Financial performance
      • 8.8.2.3 Product benchmarking
      • 8.8.2.4 Strategic initiatives
    • 8.8.3 Merck & Co., Inc.
      • 8.8.3.1 Company overview
      • 8.8.3.2 Financial performance
      • 8.8.3.3 Product benchmarking
      • 8.8.3.4 Strategic initiatives
    • 8.8.4 Clingen Group plc.
      • 8.8.4.1 Company overview
      • 8.8.4.2 Financial performance
      • 8.8.4.3 Product benchmarking
      • 8.8.4.4 Strategic initiatives
    • 8.8.5 Bristol-Mayers Squibb Company
      • 8.8.5.1 Company overview
      • 8.8.5.2 Affymetrix
      • 8.8.5.3 Company overview
      • 8.8.5.4 Financial performance
      • 8.8.5.5 Product benchmarking
      • 8.8.5.6 Strategic initiatives
    • 8.8.6 Takeda Pharmaceutical Company Limited
      • 8.8.6.1 Company overview
      • 8.8.6.2 Financial performance
      • 8.8.6.3 Product benchmarking
      • 8.8.6.4 Strategic initiatives
    • 8.8.7 Teva Pharmaceutical Industries Ltd
      • 8.8.7.1 Company overview
      • 8.8.7.2 Financial performance
      • 8.8.7.3 Product benchmarking
      • 8.8.7.4 Strategic initiatives
    • 8.8.8 F. Hoffmann-La Roche Ltd.
      • 8.8.8.1 Company overview
      • 8.8.8.2 Financial performance
      • 8.8.8.3 Product benchmarking
      • 8.8.8.4 Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제